DrugPatentWatch Database Preview
Email this page to a colleague» See Plans and Pricing
« Back to Dashboard
Plenvu is a drug marketed by Salix and is included in one NDA. There are six patents protecting this drug and one Paragraph IV challenge.
This drug has one hundred and twelve patent family members in thirty-five countries.
The generic ingredient in PLENVU is ascorbic acid; polyethylene glycol 3350; potassium chloride; sodium ascorbate; sodium chloride; sodium sulfate. There are six drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the ascorbic acid; polyethylene glycol 3350; potassium chloride; sodium ascorbate; sodium chloride; sodium sulfate profile page.
There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.
Indicators of Generic Entry
Summary for PLENVU
Recent Clinical Trials for PLENVU
Identify potential brand extensions & 505(b)(2) entrants
|Fundacion Clinic per a la Recerca Biomédica||Phase 4|
|Hospital Clinic of Barcelona||Phase 4|
|Casen Recordati S.L.||Phase 4|
Paragraph IV (Patent) Challenges for PLENVU
|PLENVU||FOR SOLUTION;ORAL||ascorbic acid; polyethylene glycol 3350; potassium chloride; sodium ascorbate; sodium chloride; sodium sulfate||209381||2018-12-06|